Digipath
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

ChrisInSF, I agree with you and Dan.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
couldbebetter Member Profile
 
Followed By 16
Posts 2,678
Boards Moderated 1
Alias Born 10/20/14
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2019 4:43:20 PM
Amarin Provides Preliminary 2018 Results and 2019 Outlook GlobeNewswire Inc. - 1/4/2019 4:15:00 PM
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 GlobeNewswire Inc. - 1/2/2019 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:35:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2018 4:08:05 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/29/2018 3:07:20 PM
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference GlobeNewswire Inc. - 11/28/2018 6:25:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/28/2018 5:24:09 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 8:59:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/26/2018 5:32:33 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 4:23:58 PM
Amarin to Present at the Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/20/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/14/2018 6:03:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 6:18:24 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... PR Newswire (US) - 11/11/2018 10:32:00 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... GlobeNewswire Inc. - 11/10/2018 3:00:00 PM
Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire Inc. - 11/8/2018 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2018 4:13:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/1/2018 7:06:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/1/2018 7:05:12 AM
Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/1/2018 5:00:00 AM
Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions ... GlobeNewswire Inc. - 10/26/2018 5:00:00 AM
couldbebetter   Saturday, 01/12/19 09:27:15 AM
Re: ChrisInSF post# 171854
Post # of 172906 
ChrisInSF, I agree with you and Dan. I believe that the best
deal we will get may be $30-$40. What gives me pause that I might
be wrong are comments from HDGabor who believes a 3 digit price is
possible. My hope is that the Pfizer rumour will result in potential
bidders getting into the door, now, rather than waiting. HDGabor has
been consistent in his view that a deal (or whatever outcome) will
most likely be known in the 1st quarter.

Over time as the market(s) for Vascepa expands both in the US and in
foreign countries, the price of Vascepa should decline. For example,
once approved in Canada, the government there will negotiate a lower
price. The same for other countries where the government picks up
the tab. In China, it was suggested in an analyst opinion, that the
retail price might have to go to $1.00 per day to be viable. Not
suggesting that will be the case, but discounting will happen and
any BP making its own internal projections is aware of that. When
I run through the numbers in my own model I do not think BP will
give AMRN the huge valuation that many here expect.

As I go over the lists of potential buyers, and it is fun to speculate,
I think it will be a company with a strong cardiovascular sales/rep
force.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist